Viatris Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Scott Andrew Smith
- Full Time Employees
- 30,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Robert J. Coury Global Center Canonsburg PA United States 15317
- IPO Date
- Feb 1, 1973
- CIK
- 0001792044
- Website
- viatris.com
- Similar Companies
- Business
- Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that develops, manufactures and markets a broad portfolio of branded and generic pharmaceuticals, biosimilars and complex generics; key brands include Lipitor, Norvasc, Viagra, Lyrica, Xanax, Creon, Celebrex, Effexor, Zoloft and EpiPen auto-injectors; generics and branded generics span therapeutic areas such as cardiovascular, central nervous system, infectious diseases, oncology, immunology, women's health, diabetes, gastroenterology, respiratory, allergy and dermatology; additional offerings encompass complex generics like Breyna (generic Symbicort), recent launches including Iron Sucrose Injection USP for iron deficiency anemia and Ryzumvi (phentolamine ophthalmic solution) for mydriasis; the company operates in developed markets, emerging markets, JANZ (Japan, Australia, New Zealand) and Greater China, supplying medicines to approximately 1 billion patients annually through global manufacturing and supply chain infrastructure. Headquartered in Canonsburg, Pennsylvania, Viatris was formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. Recent developments include the completion of the acquisition of Aculys Pharma Inc. in 2025, securing exclusive rights to pitolisant for narcolepsy and obstructive sleep apnea in Japan and Spydia Nasal Spray for status epilepticus in Japan and certain Asia-Pacific markets; submission of a New Drug Application to the U.S. FDA for a low-dose estrogen weekly patch, with anticipated approval by mid-2026; prior divestitures in 2023-2024 of its OTC business to Cooper Consumer Health, women's healthcare business and India API operations for approximately $3.6 billion; an ongoing enterprise-wide strategic review initiated in February 2025 to identify operating efficiencies in commercial, R&D, supply chain and corporate functions; and a December 2024 U.S. FDA warning letter and import alert on its Indore, India facility impacting 11 products, prompting corrective actions.
Company News
Viatris Reports Third-Quarter 2026 Financial Results
Viatris (VTRS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Viatris Announces Quarterly Dividend
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term
Here's Why Viatris (VTRS) is a Strong Value Stock
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Why Pacira BioSciences Skyrocketed Today
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
VTRS vs. AVTR: Which Stock Is the Better Value Option?
Should Value Investors Buy Viatris (VTRS) Stock?
Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?